2CARE (Coenzyme Q10 in Huntington’s Disease) Study Update
Enrollment for the 2CARE study was closed on 25 July 2012, at which time the 609th participant joined the study. The study team has met the challenge of completing enrollment for the largest and longest clinical trial in Huntington disease (HD) to date. Forty-eight sites in North America and Australia contributed to the enrollment of these participants. The study will continue until the last participant completes the study, projected in mid-2017.
The 2CARE study involves collaboration of individuals with HD, caregivers or ‘study buddies’, along with the investigators, coordinators and research staff at the participating sites.
We have come a long way since the first enrollment in April of 2008, and none of our success would have been possible without the commitment and participation of those enrolled in 2CARE. We realize that not everyone can find time to be involved in clinical trials, but thanks to the willingness of those who can, we will be able to learn whether a high dosage of coenzyme Q10 (CoQ) is effective in treating HD.
A very important requirement of being able to learn whether CoQ is effective in slowing the progression of functional decline is that we have enough people remaining in the study through the entire five years. We encourage all enrolled participants to stay committed to the study as much as possible. Remember, HD is a slowly progressive disease, so it will take time to know if there are effects of the study drug.
Beginning in the spring of 2013, we will begin to see some of the earlier enrolled participants complete their five years of participation. We deeply thank all the patients and families who are part of the study, as well as those who have made it possible in so many ways– the National Institute of Neurological Disorders and Stroke, patient advocacy organizations, site investigators, coordinators, and members of the project team.
2CARE Principal Investigators and Study Team of the Huntington Study Group